Fabricio Racca

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology · 2022 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco et al. · Nature · 2024 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Glenn J. Hanna, Anastasios Stathis, Elena López-Miranda et al. · Cancer Research Communications · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +16

The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis

Marta Vaz Batista, José Manuel Pérez-García, Laia Garrigós et al. · Med · 2024 · 39 citations

Medicine, Oncology, Pharmacotherapy +16

Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers.

Elena Miranda, Anastasios Stathis, Dagmar Hess et al. · Journal of Clinical Oncology · 2021 · 23 citations

Medicine, Oncology, Pharmacology +17